Literature DB >> 2197212

The demography of primary biliary cirrhosis in Ontario, Canada.

H Witt-Sullivan1, J Heathcote, K Cauch, L Blendis, C Ghent, A Katz, R Milner, S C Pappas, J Rankin, I R Wanless.   

Abstract

The demographics of primary biliary cirrhosis in Ontario, Canada, are described. Two hundred and twenty-five primary biliary cirrhosis patients were identified by 85 of 502 gastroenterologists (or internists) practicing in Ontario acute care hospitals that have 150 or more beds. Two hundred and six patients were verified as being antimitochondrial antibody-positive, resulting in an incidence of 3.26 per million per year and a prevalence of 22.39 per million. Questionnaire data were obtained on 88.5% of these patients. Twenty-nine percent of the patients were found to be asymptomatic. Geographical clustering and racial predisposition were not seen. No increase in breast cancer prevalence was noted. By the time the diagnosis of primary biliary cirrhosis was established, the patients had consulted a median number of 3.5 physicians. Fatigue was reported as the most disabling symptom. The diagnosis of primary biliary cirrhosis in patients referred from across the province of Ontario was independently confirmed by us, using standard criteria (antimitochondrial antibody testing and liver biopsy), and was found to be reliable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197212     DOI: 10.1002/hep.1840120116

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

3.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

4.  Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.

Authors:  E I Rigopoulou; E T Davies; A Pares; K Zachou; C Liaskos; D-P Bogdanos; J Rodes; G N Dalekos; D Vergani
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 5.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 6.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

7.  Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community.

Authors:  Henry V Chung; Mark Riley; Jin K Ho; Benjamin Leung; Gareth P Jevon; Laura T Arbour; Colin Barker; Richard Schreiber; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2007-09       Impact factor: 3.522

8.  Muscle fatigue in women with primary biliary cirrhosis: Spectral analysis of surface electromyography.

Authors:  Maria Rosa Biagini; Alessandro Tozzi; Antonello Grippo; Andrea Galli; Stefano Milani; Aldo Amantini
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

9.  Fatigue in primary biliary cirrhosis.

Authors:  K Cauch-Dudek; S Abbey; D E Stewart; E J Heathcote
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.